Anti-Seizure Drugs (ASDs) 2 Flashcards
Should be reserved for use as adjunctive therapy for focal seizures
Tiagabine
Reserved for adjunctive therapy in subjects who have failed several alternative treatments.
-Because of the visual toxicity, periodic visual assessment is required at baseline and every 3 months
Vigabatrin
Can be used as adjunctive treatment for focal seizures
-Less effective than lamotrigine
Gabapentin
Indicated as adjunctive therapy for focal seizures. It was inferior to lamotrigine as first-line therapy and should not be used as a first-line treatment
Pregabalin
Binds to Synaptic Vesicle Protein 2A (SVP2A) protein (and presumably inhibits neurotransmittor release?)
-Newer ASD
Levetiracetam
Used for adjunct therapy of partial seizures, Lennox-Gastaut syndrome and primary generalized tonic-clonic seizures
Levetiracetam (Keppra)
Levetiracetam (Keppra) is contraindicated for people with
Renal Dysfunction
Binds to AMPA receptor
-Non-competitive antagonist of glutamate
Perampanel (Fycompa)
Adjunct therapy for adults with partial seizures and generalized tonic-clonic seizures
-July 2017: approved for monotherapy for partial seizures
Perampanel (Fycompa)
The drug label has a black box warning that the drug cause may cause “serious or life-threatening psychiatric and behavioral adverse reactions, including homicidal or suicidal thoughts
Perampanel (Fycompa)
Is not FDA approved for monotherapy in the United States, it is used widely as a first-line treatment for focal and generalized tonic-clonic seizures and is approved for initial monotherapy in Europe
Levetiracetam
Indicated as adjunctive treatment for focal seizures and primary generalized tonic-clonic seizures.
-It is a new drug and should be reserved for use after failure of other ASDs
Perampanel
A medical emergency with an estimated mortality of 20% and as high as 40% in the elderly
Status Epilepticus (SE)
